NEW YORK, Jan.8 (GenomeWeb News) - ActivX Biosciences and Kyorin Pharmaceutical have signed a research agreement to study compounds for metabolic disorders, Kyorin said Tuesday.
ActivX, based in La Jolla, Calif., will use its proteomics technology to analyze the activity and toxicity mechanisms of compounds developed by Kyorin of Tokyo to treat metabolic disorders.
The two companies have already been collaborating since 2002 to study new drugs for type II diabetes.